Although whether the RNA epitranscriptome is involved in immune evasion remains unknown, these findings collectively suggest that m6A-targeted therapies combined with PD-1/PD-L1 ICIs (immune checkpoint inhibitors) could improve the effect of tumor immunotherapy. The gene discussed is CD274; the disease is neoplasm.